Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Design Therapeutics, Inc. - Common Stock (NQ:DSGN)

3.500 -0.020 (-0.57%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Design Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Design Therapeutics to Present Preclinical Data on its GeneTAC™ Small Molecule, DT-168, for the Treatment of Fuchs Endothelial Corneal Dystrophy at ARVO 2023
From Design Therapeutics, Inc.
Via GlobeNewswire
Why Design Therapeutics (DSGN) Stock Is Going Nowhere But Down
Design Therapeutics has multiple research programs and a strong drive to combat genetic disorders, but that's not enough to save DSGN stock. 
Via InvestorPlace
Short Squeeze Stocks: BBBY, SI and 3 Other Stocks Ready to Squeeze
Short squeeze stocks are all over Wall Street in the wake of the regional banking crisis. Which names should you keep an eye out for? 
Via InvestorPlace
Short Interest Update - Monday, March 27
Although equities broadly are starting the new week higher, the most heavily shorted stocks are trading lower today. 
Via Talk Markets
First Republic Bank, Blend Labs, Purple Innovation And Other Big Stocks Moving Lower On Friday
U.S. stocks traded lower, with the Dow Jones dropping more than 400 points on Friday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Why Baidu Shares Are Trading Higher By More Than 6%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Enzo Biochem, Inc. (NYSE: ENZ) gained 86.5% to $2.22 after the company announced it will sell its clinical laboratory to Labcorp. 
Via Benzinga
Design Therapeutics Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2022 Financial Results
From Design Therapeutics, Inc.
Via GlobeNewswire
Illumina, Seagen And Other Big Stocks Moving Higher On Monday
U.S. stocks traded slightly lower, with the Nasdaq Composite dropping around 0.2% on Monday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Design Therapeutics, Inc. (NASDAQ:DSGN) Investor Alert: Investigation Concerning Possible Wrongdoing
San Diego, CA -- (SBWIRE) -- 03/08/2023 -- An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Design Therapeutics, Inc. 
Via SBWire
Stocks That Hit 52-Week Lows On Wednesday
  On Wednesday, 35 stocks hit new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
  During Tuesday, 40 stocks hit new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
  On Monday, 42 companies hit new 52-week lows. 
Via Benzinga
Design Therapeutics to Participate in the SVB Securities Virtual Global Biopharma Conference
From Design Therapeutics, Inc.
Via GlobeNewswire
Design Therapeutics, Inc. (NASDAQ:DSGN) Shareholder Notice: Investigation over Possible Violations of Securities Laws
San Diego, CA -- (SBWIRE) -- 01/19/2023 -- Design Therapeutics, Inc. is under investigation over potential securities laws violations. 
Via SBWire
DESIGN ALERT: Bragar Eagel & Squire, P.C. is Investigating Design Therapeutics, Inc. on Behalf of Design Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
MillerKnoll, Cleveland-Cliffs And Some Other Big Stocks Moving Higher On Thursday
U.S. stocks traded lower, with the Dow Jones dropping over 400 points on Thursday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
$7.5 Million Bet On This Biotechnology Stock? Check Out These 3 Stocks Insiders Are Buying
Although US stocks closed mostly higher on Tuesday, there were a few notable insider trades. 
Via Benzinga
S&P 500 Rises 0.5%; Ciena Posts Upbeat Q4 Results
U.S. stocks traded higher toward the end of trading, with the NASDAQ gaining around 100 points on Thursday. 
Via Benzinga
Why Express Shares Are Trading Higher By 39%? Here Are 50 Stocks Moving In Thursday's Mid-Day Session
Gainers My Size, Inc. (NASDAQ: MYSZ) shares jumped 88% to $0.2839. My Size announced a 1-for-25 reverse stock split. 
Via Benzinga
Nasdaq Gains 100 Points; Rent the Runway Shares Spike Higher
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining over 100 points on Thursday. 
Via Benzinga
Chefs' Warehouse, Chart Industries And Some Other Big Stocks Moving Lower On Thursday
U.S. stocks traded higher, with the Dow Jones jumping over 200 points on Thursday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Dow Rises 150 Points; US Jobless Claims Increase To 230,000
U.S. stocks traded higher this morning, with the Dow Jones gaining over 150 points on Thursday. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
We're starting off the day with a look at the biggest pre-market stock movers that traders will want to watch on Thursday! 
Via InvestorPlace
Design Therapeutics Reports Positive Data from Single-Ascending Dose Trial of DT-216 for the Treatment of Friedreich Ataxia and Portfolio Progress
From Design Therapeutics, Inc.
Via GlobeNewswire
Foot Locker, Ross Stores, Palo Alto Networks, And Other Big Gainers From Friday
U.S. stocks closed higher on Friday, with the Dow Jones gaining around 200 points. Here is the list of some big stocks recording gains in the previous session. 
Via Benzinga
Design Therapeutics Highlights Pipeline Progress and Upcoming Milestones and Reports Third Quarter 2022 Financial Results
From Design Therapeutics, Inc.
Via GlobeNewswire
Design Therapeutics to Present Preclinical Data Highlighting the Potential of its GeneTAC™ Small Molecule, DT-216, for the Treatment of Friedreich Ataxia at ICAR 2022
Company On-track to Report Initial Data from Friedreich Ataxia Phase 1 Trial of DT-216 in the Fourth Quarter of 2022 
From Design Therapeutics, Inc.
Via GlobeNewswire
Why Adamis Pharmaceuticals Is Trading Lower By Around 44%, Here Are 46 Stocks Moving In Wednesday's Mid-Day Session
Gainers 
Via Benzinga
Why Stabilis Solutions Shares Jumped Over 71%; Here Are 70 Biggest Movers From Yesterday
Gainers 
Via Benzinga
Why KnowBe4 Shares Jumped Over 28%; Here Are 79 Biggest Movers From Yesterday
Gainers Ventoux CCM Acquisition Corp. (NASDAQ: VTAQ) shares jumped 54.6% to settle at $7.05 on Monday. 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.